Role of diabetes and nitric oxide release duration on analytical performance of in vivo glucose biosensors

点击翻译按钮获取中文摘要

PROJECT SUMMARY The objective of this project is to study the analytical performance benefits of nitric oxide (NO)-releasing percutaneously implanted glucose sensors in a diabetic swine model as a function of NO-release duration sensor membrane porosity, and diabetes state (i.e., insulin versus non-insulin dependent). Continuous glucose monitoring (CGM) devices with superior usability (i.e., for immediate use and extended duration) would greatly increase the ability of those afflicted with diabetes to successfully manage their disease. In the prior funding period, we demonstrated in a non-insulin dependent diabetic swine model that NO-releasing sensor membranes both lessen the FBR and facilitate improved analytical sensor performance up to 28 days—the longest duration evaluated. However, CGM devices are intended for insulin-dependent individuals and longer implantation periods would improve device utility/value. The variance in FBR and in vivo sensor performance for insulin- and non-insulin-dependent subjects is currently unknown but likely significant due to more impaired wound healing mechanisms. We hypothesize that the improvements in FBR and sensor performance that we have reported sensor membranes that release NO for 28 days will be extended to at least two months by using porous sensor membranes that release for 60+ days and passively promote healthy re-vascularization in the proximity of the sensor. Through our work, we will study the influence of both NO release and porosity on tissue biocompatibility and sensor performance as a function of diabetes. In this respect, we will generate new knowledge on how diabetes influences the tissue integration and in vivo sensor performance.